IRIS UniCatt

Fargnoli, Maria Concetta
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.079
AS - Asia 2.989
EU - Europa 1.607
SA - Sud America 582
AF - Africa 102
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 4
Totale 8.368
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.979
SG - Singapore 1.534
CN - Cina 551
BR - Brasile 492
SE - Svezia 302
IT - Italia 264
VN - Vietnam 245
DE - Germania 232
FR - Francia 194
IN - India 134
IE - Irlanda 122
GB - Regno Unito 117
HK - Hong Kong 113
JP - Giappone 104
FI - Finlandia 86
ID - Indonesia 85
RU - Federazione Russa 69
CA - Canada 45
BD - Bangladesh 41
AR - Argentina 36
MX - Messico 35
AT - Austria 32
KR - Corea 30
BE - Belgio 27
PL - Polonia 27
CI - Costa d'Avorio 26
ZA - Sudafrica 26
IQ - Iraq 24
ES - Italia 22
CZ - Repubblica Ceca 21
NL - Olanda 21
TR - Turchia 21
SA - Arabia Saudita 15
EC - Ecuador 14
PK - Pakistan 14
CO - Colombia 12
UA - Ucraina 12
CH - Svizzera 11
KE - Kenya 11
RO - Romania 11
AE - Emirati Arabi Uniti 10
EG - Egitto 9
UZ - Uzbekistan 9
VE - Venezuela 9
LT - Lituania 8
MA - Marocco 8
PE - Perù 8
JM - Giamaica 7
JO - Giordania 7
MY - Malesia 7
IL - Israele 5
KZ - Kazakistan 5
TN - Tunisia 5
DZ - Algeria 4
PH - Filippine 4
AL - Albania 3
AU - Australia 3
CL - Cile 3
CR - Costa Rica 3
DK - Danimarca 3
GH - Ghana 3
GT - Guatemala 3
IR - Iran 3
LB - Libano 3
NG - Nigeria 3
NO - Norvegia 3
NP - Nepal 3
PA - Panama 3
PY - Paraguay 3
TW - Taiwan 3
UY - Uruguay 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AO - Angola 2
AZ - Azerbaigian 2
BA - Bosnia-Erzegovina 2
BG - Bulgaria 2
BH - Bahrain 2
BN - Brunei Darussalam 2
BO - Bolivia 2
EU - Europa 2
GR - Grecia 2
HU - Ungheria 2
KG - Kirghizistan 2
MM - Myanmar 2
NZ - Nuova Zelanda 2
PT - Portogallo 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
SY - Repubblica araba siriana 2
BB - Barbados 1
BS - Bahamas 1
BY - Bielorussia 1
CG - Congo 1
EE - Estonia 1
ET - Etiopia 1
GA - Gabon 1
GM - Gambi 1
IM - Isola di Man 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
Totale 8.357
Salva come PNG Salva come JPEG
Città #
Singapore 847
Chandler 420
San Jose 389
Ashburn 262
Dallas 161
Beijing 151
Dublin 122
Hong Kong 109
New York 107
Ann Arbor 98
Tokyo 98
Lauterbourg 90
Jakarta 80
Hefei 79
Los Angeles 74
Ho Chi Minh City 72
Hanoi 67
Hyderabad 64
Boston 62
Milan 58
Bremen 56
Frankfurt am Main 56
Princeton 52
Helsinki 51
Rome 50
San Mateo 46
São Paulo 45
The Dalles 39
Munich 38
Moscow 37
Chicago 35
Wilmington 32
Seoul 29
St Louis 28
London 27
Abidjan 26
Kent 26
Nuremberg 25
Brussels 24
Houston 23
Santa Clara 23
North Bergen 22
Brooklyn 21
Paris 21
Lappeenranta 20
Atlanta 19
Mexico City 19
Orem 18
Woodbridge 17
Vienna 16
Brno 15
Montreal 15
Poplar 15
Washington 15
Cattolica 14
Amsterdam 13
Da Nang 13
Düsseldorf 13
Rio de Janeiro 13
Warsaw 13
Chennai 12
Denver 12
Portsmouth 12
Seattle 12
Stockholm 12
Belo Horizonte 11
Falkenstein 11
Jacksonville 11
Johannesburg 11
Nairobi 11
Toronto 11
Turku 11
Wroclaw 11
Baghdad 10
Nanjing 10
New Delhi 10
Phoenix 10
San Francisco 10
Brasília 9
Council Bluffs 9
Curitiba 9
Haiphong 9
Jeddah 9
Manchester 9
Redwood City 9
Ribeirão Preto 9
Saint Cloud 9
Mountain View 8
Mumbai 8
Tashkent 8
Amman 7
Ankara 7
Bexley 7
Guangzhou 7
Kingston 7
Quito 7
Salvador 7
Shanghai 7
Birmingham 6
Cape Town 6
Totale 4.861
Salva come PNG Salva come JPEG
Nome #
Real-life efficacy and safety of ingenol mebutate for the treatment of actinic keratosis of the face and scalp: A single arm retrospective study 204
A new dermoscopic algorithm for the differential diagnosis of facial lentigo maligna and pigmented actinic keratosis 161
Real-world evidence of biologic treatments in moderate–severe psoriasis in Italy: Results of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: An obserVAtional longitudinal study of real-life clinical practice) study 152
Cutaneous squamous cell carcinoma. Italian guidelines by SIDeMaST adapted to and updating EADO/EDF/EORTC guidelines 151
European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment-Update 2023 136
European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention 129
Management of cutaneous melanoma: Comparison of the leading international guidelines updated to the 8th American Joint Committee on Cancer staging system and workup proposal by the Italian Society of Dermatology 125
A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudinal study 122
Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation 121
Advanced Cutaneous Squamous Cell Carcinoma: Italian Multicentric Retrospective Analysis of Patient Profiles and Therapeutic Approaches 119
Pruritus characteristics in a large Italian cohort of psoriatic patients 119
A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis 118
Sclerosing nevus with pseudomelanomatous features: dermoscopic and confocal aspects 113
Molecular genetics of cutaneous squamous cell carcinoma: perspective for treatment strategies 112
Clinical Characteristics of an Italian Patient Population with Advanced BCC and Real-Life Evaluation of Hedgehog Pathway Inhibitor Safety and Effectiveness 111
Disease Severity Is Associated with Alexithymia in Patients with Atopic Dermatitis 110
Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: results from extension phase of the SUPREME study 107
"Your Skin Tells You" Campaign for Keratinocyte Cancers: When Individuals' Selection Makes the Difference 105
Expression of IL-23/Th17-related cytokines in basal cell carcinoma and in the response to medical treatments 105
Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational study 105
A 52-week update of a multicentre Italian real-world experience on effectiveness and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis 105
European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics – Update 2019 104
Fast Clinical Response of Bimekizumab in Nail Psoriasis: A Retrospective Multicenter 36-Week Real-Life Study 103
The dynamics of circulating tumour DNA (ctDNA) during treatment reflects tumour response in advanced melanoma patients 103
European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma—update 2023 102
Characterization of melanoma susceptibility genes in high-risk patients from Central Italy 102
Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma 102
Assessing the beneficial impact of a patient support program in secukinumab-treated patients with psoriasis in italy 102
Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation 100
Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study 100
European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022 98
5-aminolaevulinic acid patch photodynamic therapy for the treatment of actinic keratoses: preliminary results from an italian study in the real-life setting 98
Real-life effectiveness and safety of baricitinib in patients with severe alopecia areata: A 24-week Italian study 97
Coding and noncoding somatic mutations in candidate genes in basal cell carcinoma 97
Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis 97
Psoriasis and its management in women of childbearing age: Tools to increase awareness in dermatologists and patients 95
Successful response of upadacitinib in different clinical phenotypes of atopic dermatitis 95
Bimekizumab for the Treatment of Plaque Psoriasis with Involvement of Genitalia: A 16-Week Multicenter Real-World Experience - IL PSO (Italian Landscape Psoriasis) 94
Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations 94
Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: Data from the DA-COVID-19 registry 93
Efficacy and safety of Vismodegib treatment in patients with advanced basal cell carcinoma and multiple comorbidities 93
Heterogeneity of BRAF, NRAS, and TERT Promoter Mutational Status in Multiple Melanomas and Association with MC1R Genotype: Findings from Molecular and Immunohistochemical Analysis 91
European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment – Update 2019 91
Position statement on classification of basal cell carcinomas. Part 1: unsupervised clustering of experts as a way to build an operational classification of advanced basal cell carcinoma based on pattern recognition 91
Real-World Apremilast Use for Treatment of Plaque Psoriasis in Italy: Patient Perspective, Characteristics, and Clinical Outcomes from the DARWIN Study 90
Efficacy and Safety of bimekizumab in elderly patients: real-world multicenter retrospective study–IL PSO (Italian Landscape Psoriasis) 89
Treatment adherence with diclofenac 3% gel among patients with multiple actinic keratoses: an integrated low-intensity intervention program versus standard-of-care 89
"Your Skin Tells You" Campaign for Keratinocyte Cancers: When Individuals' Selection Makes the Difference 88
Molecular alterations in basal cell carcinoma subtypes 88
Clinical determinants of complete response to vismodegib in locally advanced basal cell carcinoma: a multicentre experience 88
Combining common genetic variants and non-genetic risk factors to predict risk of cutaneous melanoma 86
Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility 86
Novel MAPK/AKT-impairing germline NRAS variant identified in a melanoma-prone family 85
Self-Assessment Questionnaire on Patient-Physician Concordance on Nevus Self-Count and Models Development to Predict High-Risk Phenotype >50 Nevi 84
Mycosis fungoides: creation of a prospective, interdisciplinary and multicenter study in central Italy 84
Patient satisfaction with calcipotriol/betamethasone dipropionate cutaneous foam for the treatment of plaque psoriasis: The LION real-life multicenter prospective observational cohort study 84
European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022 83
ΜelanoQ: A Consensus Questionnaire of Standardized Epidemiologic and Clinical Variables for Melanoma Risk Assessment by the MelaNostrum Consortium 83
A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16-week real-life experience during the COVID-19 pandemic 83
Comment on ‘Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines’ 82
Response to: Comment on ‘Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines’ 79
Position statement on classification of basal cell carcinomas. Part 2: EADO proposal for new operational staging system adapted to basal cell carcinomas 79
Correction to: Comorbidities and treatment patterns in adult patients with atopic dermatitis: results from a nationwide multicenter study (Archives of Dermatological Research, (2022), 314, 6, (593-603), 10.1007/s00403-021-02243-w) 78
Beneficial effects of upadacitinib on alopecia areata associated with atopic dermatitis: A multicenter retrospective study 78
Long-term efficacy and safety of daylight photodynamic therapy with methyl amninolevulinate for actinic keratosis of the face and scalp 78
Telomeres and telomerase in cutaneous squamous cell carcinoma 78
Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline – Update 2022 77
Satisfaction and attitudes toward systemic treatments for psoriasis: A cross-sectional study 77
The role of insomnia in the vulnerability to depressive and anxiety symptoms in atopic dermatitis adult patients 76
Comorbidities and treatment patterns in adult patients with atopic dermatitis: results from a nationwide multicenter study 76
Corrigendum: “Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma” (European Journal of Cancer (2021) 157 (250–258), (S0959804921005360), (10.1016/j.ejca.2021.08.018)) 75
Update on the Management of Pediatric Psoriasis: An Italian Consensus 75
Contribution of common genetic variants to familial aggregation of disease and implications for sequencing studies 74
Italian National Registry of Alopecia Areata: an epidemiological study of 699 Italian patients 73
Assessing a measure for Quality of Life in patients with severe Alopecia Areata: a multicentric Italian study 73
The Risk of Candidiasis During Treatment with Bimekizumab for the Management of Plaque Psoriasis: A 16-Week Multicenter Real-World Experience - IL PSO (Italian Landscape Psoriasis) 72
Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus Statement 72
AtopyReg®: the prospective Italian patient registry for moderate to severe atopic dermatitis in adults by SIDeMaST 71
Italian expert consensus paper on the management of patients with actinic keratoses 70
Effectiveness of tildrakizumab 200 mg: an Italian multicenter study 69
Dermoscopic similarity is an independent predictor of BRAF mutational concordance in multiple melanomas 66
Germline ATM variants predispose to melanoma: a joint analysis across the GenoMEL and MelaNostrum consortia 65
High- and intermediate-risk susceptibility variants in melanoma families from the Mediterranean area: A multicentre cohort from the MelaNostrum Consortium 61
The association between COVID-19 lockdowns and melanoma diagnosis and thickness: A multicenter retrospective study from Europe 60
Efficacy and safety of switching to ixekizumab in secukinumab nonresponder patients with psoriasis: results from a multicentre experience 56
Use of upadacitinib in the treatment of moderate to severe atopic dermatitis: patient profiling, dose selection, and therapy modulation, what does real-life teach us? 53
Prevalence of pathogenic/likely pathogenic variants in the 24 cancer genes of the ACMG Secondary Findings v2.0 list in a large cancer cohort and ethnicity-matched controls 50
A long-term real-world safety study of guselkumab in patients with psoriasis who have infectious comorbidities, malignancies or heart disease: The EARLY study 48
Prevalence and risk factors of actinic keratosis in patients attending Italian dermatology clinics 47
Gender Influence on Bimekizumab Response in Patients with Psoriasis: Results of a Real-World Multicenter Retrospective Study—IL PSO (Italian Landscape PSOriasis) 46
Predictive Factors for Super Responder Status and Long-Term Effectiveness of Guselkumab in Psoriasis: A Multicenter Retrospective Study 44
Effectiveness and safety of baricitinib in severe alopecia areata: 48-week results 40
Effectiveness of Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: A Retrospective, Real-World Multicenter Study with a Focus on Obese and Multi-Failure Patients—IL PSO (Italian Landscape Psoriasis) 39
BRodalumab effectiveness in psoriatic patients that experienced anti-IL17 Intra-Class failure: a multicentre, retrospective study (BRIC - Study) IL-PSO (Italian Landscape Psoriasis) 37
Effectiveness, speed of action and safety of brodalumab in elderly psoriasis patients: a multicenter real-world study–IL PSO (Italian Landscape Psoriasis) 37
Super Responder Profile Under Bimekizumab Treatment in Moderate-to-Severe Psoriasis: A Short Term Real-Life Observation—IL PSO (Italian Landscape Psoriasis) 25
Totale 8.518
Salva come PNG Salva come JPEG
Categoria #
all - tutte 38.326
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 38.326
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202135 0 0 0 0 0 0 0 0 0 0 29 6
2021/2022445 15 8 8 17 29 8 1 66 32 35 111 115
2022/20231.023 111 134 75 184 77 124 29 86 146 16 31 10
2023/2024751 26 184 52 54 47 104 55 10 15 27 88 89
2024/20251.762 41 28 107 56 151 115 60 77 268 206 363 290
2025/20264.175 604 226 238 497 771 266 714 211 316 291 41 0
Totale 8.518